他汀類藥物是最廣泛的可用藥物治療降低膽固醇水平，并控制其發(fā)展的處方藥。所有的他汀類藥物，如阿托伐他汀、氟伐他汀、洛伐他汀、匹伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀可用于心血管疾病事件的預防。眾所周知，在治療過程中一些服用他汀類藥物的患者出現(xiàn)不良反應，如肝損害、癌癥的風險和骨骼肌損害。因此，認識他汀類藥物的安全性風險是很重要的。根據(jù)發(fā)表的他汀類藥物的臨床研究文獻數(shù)據(jù)，分析和認識這類藥物的安全性、不良反應及毒性的風險，并簡要介紹了由美國心臟協(xié)會和美國心臟病學院基于4年評述而制定的2013年他汀類降膽固醇藥物新使用指南。

Statins are the most widely prescribed drug available pharmacotherapy for the management of high blood cholesterol levels virtually since their development. All of statin-drugs, such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin used for prevention of cardiovascular disease event. As all know, some of the patients taking statins experience adverse effects during therapy. Such as liver toxicity, muscle injury and increased cancer risk are the top adverse effects. Therefore, it is important to understand the risks involved with the drug class and individual statins. This paper analyzes and understands the risks on safety, adverse effects and toxicity of statins from published the clinical research data in the literatures. And it also introduced to evaluate information of use and risks of statins and the "2013 Guidelines on Statins Drop Cholesterol Targets" based on a four-year review of the evidence formulated by the American Heart Association and the American College of Cardiology.

劉昌孝，中國工程院院士，從事新藥研發(fā)、藥物代謝動力學和新藥評價研究工作。Tel：（022）23006863E-mail：liuchangxiao@163.com